U.S. markets closed
  • S&P 500

    4,397.94
    -84.79 (-1.89%)
     
  • Dow 30

    34,265.37
    -450.02 (-1.30%)
     
  • Nasdaq

    13,768.92
    -385.10 (-2.72%)
     
  • Russell 2000

    1,987.92
    -36.12 (-1.78%)
     
  • Crude Oil

    84.83
    -0.72 (-0.84%)
     
  • Gold

    1,836.10
    -6.50 (-0.35%)
     
  • Silver

    24.34
    -0.37 (-1.50%)
     
  • EUR/USD

    1.1348
    +0.0031 (+0.27%)
     
  • 10-Yr Bond

    1.7470
    -0.0860 (-4.69%)
     
  • GBP/USD

    1.3555
    -0.0045 (-0.33%)
     
  • USD/JPY

    113.6500
    -0.4500 (-0.39%)
     
  • BTC-USD

    34,941.38
    -1,434.41 (-3.94%)
     
  • CMC Crypto 200

    870.86
    +628.18 (+258.85%)
     
  • FTSE 100

    7,494.13
    -90.88 (-1.20%)
     
  • Nikkei 225

    27,522.26
    -250.67 (-0.90%)
     

Pasithea Therapeutics Stock Skyrockets On Nasal Spray Approval

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • KTTA

By Sam Boughedda

Investing.com — Shares of Pasithea Therapeutics Corp (NASDAQ:KTTA) have skyrocketed Tuesday after announcing that its subsidiary Pasithea Clinics has been approved to provide esketamine nasal spray (SPRAVATO) for treatment-resistant depression in adults.

Pasithea shares shot up 220%, to around $7.08

The biotechnology firm, which focuses on treatments for psychiatric and neurological disorders, said it has started offering the treatment in its Knightsbridge, London, location — becoming only one of three clinics in the U.K. approved to provide the treatment.

Pasithea CEO Dr. Tiago Reis Marques called the approval an "important milestone" for its U.K. clinics and their patients.

Last week, Pasithea revealed that Pasithea Clinics has launched an in-home intravenous ketamine therapy for patients suffering from similar treatment-resistant mental health issues.

Related Articles

Pasithea Therapeutics Stock Skyrockets On Nasal Spray Approval

France stocks lower at close of trade; CAC 40 down 0.85%

U.S. tech execs hone approach to counter unions amid growing worker interest